advertisement
11.16 Vehicles, delivery systems, pharmacokinetics, formulation (29)
Showing records 1 to 25
Search within classification 11.16 Vehicles, delivery systems, pharmacokinetics, formulation47862 Challenges in the clinical measurement of ocular surface disease in glaucoma patients
Pflugfelder SC; Baudouin C
Clinical Ophthalmology 2011; 5: 1575-1583
48266 Corneal sensitivity in patients treated medically for glaucoma or ocular hypertension
Van Went C; Alalwani H; Brasnu E; Pham J; Hamard P; Baudouin C; Labbé A
Journal Français d'Ophtalmologie 2011; 34: 684-690
47931 Incidence of new coding for dry eye and ocular infection in open-angle glaucoma and ocular hypertension patients treated with prostaglandin analogs: retrospective analysis of three medical/pharmacy claims databases
Schwartz GF; Kotak S; Mardekian J; Fain JM
BMC Ophthalmology 2011; 11: 14
47832 Economic outcomes of glaucoma treatment with prostaglandin eye drops preserved with polyquad(registered trademark) instead of benzalkonium chloride in Germany
Gerlier L; Lamotte M; Lorenz K; Berdeaux G; Verboven Y; Pfeiffer N
Value in Health 2011; 14: A503
48030 In vivo and ocular safety study of dorsolamide HCL ocular insert
Ghelani TK; Seth AK; Saini V; Kumar S; Yadav YC; Singhal S
Pharmacologyonline 2011; 2: 1179-1187
48398 Periocular injection of in situ hydrogels containing Leu-Ile, an inducer for neurotrophic factors, promotes retinal ganglion cell survival after optic nerve injury
Nakatani M; Shinohara Y; Takii M; Mori H; Asai N; Nishimura S; Furukawa-Hibi Y; Miyamoto Y; Nitta A
Experimental Eye Research 2011; 93: 873-879
47824 Pharmacokinetics of pirfenidone after topical administration in rabbit eye
Sun G; Lin X; Zhong H; Yang Y; Qiu X; Ye C; Wu K; Yu M
Molecular Vision 2011; 17: 2191-2196
47608 The extended ocular hypotensive effect of positive liposomal cholesterol bound timolol maleate in glaucomatous rabbits
Shafaa MW; Sabra NM; Fouad RA
Biopharmaceutics and Drug Disposition 2011; 32: 507-517
48336 Comparative in vitro toxicology study of travoprost polyquad-preserved, travoprost BAK-preserved, and latanoprost BAK-preserved ophthalmic solutions on human conjunctival epithelial cells
Brignole-Baudouin F; Riancho L; Liang H; Baudouin C
Current Eye Research 2011; 36: 979-988
48037 Sustained release of an Anti-Glaucoma drug: Demonstration of efficacy of a liposomal formulation in the rabbit eye
Natarajan JV; Chattopadhyay S; Ang M; Darwitan A; Foo S; Zhen M; Koo M; Wong TT; Venkatraman SS
PLoS ONE 2011; 6:9 Article Number: e24513
47881 Advances in preservative-free glaucoma drops
Stefan C; Pop A; Cojocaru I
Oftalmologia 2011; 55: 3-6
47683 Challenge and treatment strategy for ocular surface damage in patients with long term use of antiglaucoma drugs
He XG
Chinese Journal of Ophthalmology 2011; 47: 101-104
47580 Effect of ion pairing on in vitro transcorneal permeability of a (Delta)(9)-tetrahydrocannabinol prodrug: Potential in glaucoma therapy
Hingorani T; Gul W; Elsohly M; Repka MA; Majumdar S
Journal of Pharmaceutical Sciences 2011;
48004 Ophthalmic preservatives: Focus on polyquaternium-1
Rolando M; Crider JY; Kahook MY
Expert Opinion on Drug Delivery 2011; 8: 1425-1438
48070 Effects of antiglaucoma drugs on the ocular surface in rabbits: a fixed-combination drug versus two concomitant drugs
Cho HK; Park MH; Moon JI
Japanese Journal of Ophthalmology 2011; 55: 670-675
47599 Chitosan nanoparticles for controlled delivery of brimonidine tartrate to the ocular membrane
Singh KH; Shinde UA
Pharmazie 2011; 66: 594-599
47779 Patient acceptance and attitude toward an alternative method of subconjunctival injection for the medical treatment of glaucoma
Chong RS; Su D; Tsai A; Jiang Y; Htoon HM; Lamoureux EL; Aung T; Wong TT
Journal of Glaucoma 2011;
47753 Pharmacokinetics of antiglaucoma medications
Sachdev M; Yadava U; Bamrolia N
Journal of Current Glaucoma Practice 2011; 5: 21-26
48002 Nanotechnology in ocular delivery: Current and future directions
Sultana Y; Maurya DP; Iqbal Z; Aqil M
Drugs of Today 2011; 47: 441-455
47887 Antiglaucoma drugs: The role of preservative-free formulations
Bagnis A; Papadia M; Scotto R; Traverso CE
Saudi Journal of Ophthalmology 2011; 25: 389-394
47852 Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma
Gandolfi S; Paredes T; Goldberg I; Coote M; Wells A; Volksone L; Pillai MR; Stalmans I; Denis P
European Journal of Ophthalmology 2011; 22: 34-44
47835 A systematic review of observational studies of patients with ocular hypertension or glaucoma receiving long term topical eye therapies
Christova L; Cottrell S; Mudge M; Tilden D; Harvey C
Value in Health 2011; 14: A510
47833 Longer term patient benefits of polyquad(registered trademark) preservative instead of benzalkonium chloride in prostaglandin eye drops: A microsimulation model in ocular hypertension and open-angle glaucoma
Gerlier L; Lamotte M; Berdeaux G; Verboven Y; Pfeiffer N
Value in Health 2011; 14: A502
47812 Detection of raman spectra in ocular drugs for potential in vivo application of raman spectroscopy
Elshout M; Erckens RJ; Webers CA; Beckers HJ; Berendschot TT; de Brabander J; Hendrikse F; Schouten JS
Journal of Ocular Pharmacology and Therapeutics 2011; 27: 445-451
47996 Prodrugs - An efficient way to breach delivery and targeting barriers
Huttunen KM; Rautio J
Current Topics in Medicinal Chemistry 2011; 11: 2265-2287
